Put Buying in AstraZeneca (AZN) Suggests Near-Term Bearish Bias in Shares -Susquehanna

AstraZeneca (AZN) Says IMFINZI Granted Breakthrough Therapy Designation by US FDA for Patients with Locally Advanced Unresectable NSCLC

July 31, 2017 7:05 AM EDT

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for IMFINZI (durvalumab), an anti-PD-L1 monoclonal antibody, being investigated for the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: For patients who have not progressed following chemoradiation therapy the only current option is active monitoring. Unfortunately, for the majority of patients, their cancer will progress to... More

AstraZeneca (AZN) Announces FDA Breakthrough Therapy Designation for Imfinzi in NSCLS

July 31, 2017 6:09 AM EDT

AstraZeneca (NYSE: AZN) and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Imfinzi(durvalumab) for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: For patients who have not progressed following chemoradiation therapy the only current option is active monitoring.... More

Morgan Stanley Downgrades AstraZeneca (AZN) to Equalweight

July 28, 2017 7:55 AM EDT

Morgan Stanley downgraded AstraZeneca (NYSE: AZN) from Overweight to Equalweight.

The price target is reduce from GBP 5600 to GBP 4700.

For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.

Shares of AstraZeneca closed at $28.88 yesterday.

... More

Dividends a worry at drugmakers Astra, GSK after dramatic week

July 28, 2017 6:36 AM EDT

By Ben Hirschler

LONDON (Reuters) - Britain's two big drugmakers face very different challenges but they share a common problem: how to convince investors that their dividends are safe.

With both stocks offering a dividend yield of more than 5 percent, AstraZeneca and GlaxoSmithKline provide islands of decent income in a sea of low returns.

The chief executives of both companies faced a barrage of questions from analysts about future payouts and were forced to defend their dividend strategies at post-results meetings this week.

AstraZeneca was grilled on the topic four times and GSK five times... More

Merck (MRK) Likely Out as Potential Suitor for TESARO (TSRO) or Clovis (CLVS) After AstraZeneca Collaboration - Credit Suisse

July 27, 2017 10:01 AM EDT

Credit Suisse analyst Alethia Young said news that Merck (NYSE: MRK) announced a multi-billion dollar PARP joint venture with AstraZeneca (NYSE: AZN) suggest that Merck won't buy TESARO (NASDAQ: TSRO) or Clovis... More

Leerink Partners Downgrades AstraZeneca (AZN) to Market Perform

July 27, 2017 9:53 AM EDT

Leerink Partners downgraded AstraZeneca (NYSE: AZN) from Outperform to Market Perform with a price target of $31.00 (from $36.00).

For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.

Shares of AstraZeneca closed at $33.94 yesterday.

... More